Trials / Completed
CompletedNCT03740230
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
Post-marketing Surveillance to Assess the Safety and Effectiveness of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the "Standard for Re-examination of New Drugs"
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,134 (actual)
- Sponsor
- AbbVie · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
Post-marketing surveillance study to evaluate the real world safety and effectiveness of Maviret (Glecaprevir/Pibrentasvir) administered under a normal, routine treatment practice by Korean patients with Chronic Hepatitis C Genotypes 1 to 6
Detailed description
Patients with type C hepatitis genotypes 1-6 who had been prescribed Maviret (glecaprevir/pibrentasvir) in accordance with approved local label. The sample size for this study is due to a requirement by local authorities.
Conditions
Timeline
- Start date
- 2018-09-26
- Primary completion
- 2023-07-21
- Completion
- 2023-07-21
- First posted
- 2018-11-14
- Last updated
- 2024-07-19
Locations
61 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03740230. Inclusion in this directory is not an endorsement.